Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Sets March Date for Shareholder Meeting


Vermillion said this week that it will hold its 2012 shareholder meeting on March 21.

The scheduling of the meeting had become an issue for the company recently, with Vermillion last week receiving a notice from the Nasdaq Stock Market that it was not in compliance with the exchange's listing rule that companies hold an annual shareholder meeting no later than one year after the end of their fiscal year.

Also last week, Vermillion shareholder George Bessenyei brought an action against the company in the Delaware Court of Chancery to force it to hold its annual meeting (PM 1/11/2013).

At the meeting, one board seat will be up for election. The company has nominated Roberta Della Vedova for election to the seat. Vedova is the vice president of human resources and head of global diagnostic sales at biotech firm eBiosciences. She was also a co-founder of tumor testing firm AlliedPath.

Bessenyei and his fellow shareholders Gregory Novak and Robert Goggin have filed documents indicating they plan to nominate Goggin for the open seat. Goggin is a lawyer and an owner and director of Philadelphia-based law firm Keller & Goggin.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.